Place de cotation: WIRT - CHF
Indice: SMI
- Stoxx 50
Novartis
figure parmi les leaders mondiaux dans le secteur pharmaceutique.
-
produits pharmaceutiques : maladies cardio-vasculaires, dysfonctionnements
du système nerveux central, dermatologie, oncologie, maladies respiratoires,
dysfonctionnements hormonaux, etc. Novartis possède par ailleurs
près de 50 molécules en phases d'études cliniques
-
médicaments génériques )
-
para-pharmacie (: produits nutritionnels , produits OTC et autres
-
ophtalmologie . Ciba Vision est le n° 2 mondial des lentilles de contact.
Le groupe commercialise également des solutions de nettoyage pour
lentilles (20% du CA de la branche)
-santé
animale
Tasigna®
receives US approval providing new hope to chronic myeloid leukemia patients
with resistance or intolerance to existing therapies
Tasigna
produced responses in 40% of patients with Philadelphia chromosome-positive
chronic myeloid leukemia resistant or intolerant to prior treatment
Approval
and availability in US means Novartis can offer physicians and patients
a comprehensive treatment approach for this disease
Basel,
October 29, 2007 - Tasigna® (nilotinib) has been approved in the US
as a new anti-cancer therapy for certain patients with a life-threatening
form of leukemia who are resistant or intolerant to prior treatment including
Glivec® (imatinib)*, an established treatment standard and a leading
Novartis medicine.
Novartis
will make Tasigna available throughout the US within days following this
approval by the Food and Drug Administration (FDA) to meet the treatment
needs of these patients with Philadelphia chromosome-positive (Ph+) chronic
myeloid leukemia (CML).
CML
is one of the four most common types of leukemia, a form of blood cancer,
and affects around 4,500 people in the US each year[1].
"Tasigna
represents an important advance for the small number of patients who are
resistant or intolerant to prior therapy," said David Epstein, President
and CEO of Novartis Oncology. "This approval means we can offer physicians
a comprehensive treatment approach with effective medicines to treat their
Ph+ CML patients."
Taken
twice daily, Tasigna works by inhibiting the proliferation of cells containing
an abnormal chromosome. It does this by targeting the production of the
Bcr-Abl protein, which is produced only by cells containing the abnormal
Philadelphia chromosome. This protein is recognized as the key cause and
driver of the overproduction of cancer-causing white blood cells in patients
with Ph+ CML.
Tasigna
was specifically designed to target the Bcr-Abl protein more preferentially
than Glivec without adding new mechanisms of action. At six months follow-up,
Tasigna reduced or eliminated cells carrying the abnormal Philadelphia
chromosome in 40% of patients in chronic phase of the disease.
Applying
experience gained from the development of Glivec, which remains the most
frequently prescribed treatment for patients with CML, a team of Novartis
scientists created Tasigna in August 2002, just a year after the launch
of Glivec. In preclinical studies, the medicine was able to overcome resistance
resulting from Bcr-Abl kinase mutations in 32 of 33 cell lines commonly
associated with Ph+ CML. Patients with a variety of these mutations also
responded to treatment with Tasigna.
Novartis
announces the retirement of Urs Baerlocher
Urs
Baerlocher, a member of the Executive Committee of Novartis since 1999,
retires as of August 31
Basel,
August 29, 2007 - Novartis announced today the retirement of Dr. Urs Baerlocher,
who was a member of the Executive Committee of Novartis and most recently
Head of Legal and Tax Affairs. He will retire at the end of August at the
age of 65.
Dr.
Thomas Werlen, 42, General Counsel of Novartis since January 2006 will
now directly report to Dr. Daniel Vasella, Chairman and Chief Executive
Officer of Novartis. He previously reported to Urs Baerlocher. Barbara
Kessler, Head of Group Tax and Insurance will report to Dr. Raymund Breu,
Group CFO.
"I
want to thank Urs Baerlocher for his contributions in overseeing several
strong global functions for Novartis. He built a solid legal and tax function,
and his skills were particularly helpful in several of our strategic initiatives.
Following our signing of the UN Global Compact, Urs Baerlocher advanced
our
implementation of Novartis' strong Code of Conduct," said Dr. Daniel Vasella,
Chairman and CEO of Novartis.
After
working as a tax attorney in Solothurn, Urs Baerlocher joined Sandoz in
1973 and held positions of increasing responsibility, including CEO of
the Sandoz Nutrition division and CEO of Sandoz Pharma while also serving
on the Sandoz Executive Board. At Novartis, he was named a member of the
Executive Committee in 1999.
Prior
to joining Novartis, Dr. Thomas Werlen was a partner in the London office
of the international law firm Allen & Overy LLP. He also worked at
other law firms in Switzerland and the US. He has a Ph.D in law from the
University of Zurich and earned a master's degree from Harvard Law
School. He is a member of the New York and the Swiss bar
17/07/07
Novartis delivers strong performance in first half of 2007 (H1 - Report)
Group
first-half net sales advance 14% (+11% in local currencies) to USD 19.9
billion on solid contributions from all divisions
Net
income up 14% to USD 4.2 billion and EPS rises 14% to USD 1.78 per share
Operating
income from continuing operations up 13% and net income from continuing
operations advances 17%
New
pharmaceutical brands - particularly Tekturna, Lucentis, Exjade and Exforge
- performing dynamically; seven major regulatory approvals achieved to
date in 2007
Proceeds
from non-core divestments to fund targeted acquisitions and repurchase
of up to approximately USD 4 billion of Novartis shares by February 2008
Outlook
maintained for record 2007 operating and net income for continuing operations;
Group net sales growth revised to mid-single-digits in local currencies
Pharmaceuticals
net sales growth expected to slow in second half of 2007, mainly from US
generic competition for Lotrel and Lamisil and the Zelnorm suspension
Key
Group figures
First
half
H1
2007 H1 2006 % Change USD m % of
net
sales USD m % of
net
sales USD lc
Net
sales 19 941 17 483 14 11
Operating
income 4 669 23.4 4 262 24.4 10
Net
income 4 187 21.0 3 669 21.0 14
Basic
earnings per share/ADS USD
1.78
USD
1.56
14
Second
quarter
Q2 2007 Q2 2006 % Change USD m % of
net
sales USD m % of
net
sales USD lc
Net
sales 10 122 9 182 10 7
Operating
income 2 216 21.9 2 060 22.4 8
Net
income 2 016 19.9 1 713 18.7 18
Basic
earnings per share/ADS USD
0.86
USD
0.73
18
Basel,
July 17, 2007 - Commenting on the results, Dr. Daniel Vasella, Chairman
and CEO of Novartis said: "All areas of our strategic healthcare portfolio
performed well in the first half of 2007 despite some setbacks in the Pharmaceuticals
Division. Continuing our focus on innovation, we have already achieved
seven major regulatory approvals this year and more are expected in the
second half. Many of these new products are meeting high expectations,
while our leading brands Diovan and Gleevec/Glivec keep growing dynamically.
Sandoz and Vaccines and Diagnostics again delivered strong growth. Our
complementary healthcare businesses are positioning us well to fulfill
a broad spectrum of patient needs and meet the challenges of an increasingly
volatile sector."
First
half 2007
Net
sales H1 2007 H1 2006 %
Change USD m USD m USD lc
Pharmaceuticals
11 988 10 751 12 9
Vaccines
and Diagnostics 482 127
Sandoz
3 415 2 881 19 13
Consumer
Health continuing operations 2 643 2 415 9 6
Net
sales from continuing operations 18 528 16 174 15 11
Consumer
Health discontinuing operations(1) 1 413 1 309 8 7
Total
19 941 17 483 14 11
(1)
Discontinuing operations include Medical Nutrition and Gerber in 2007 and
Medical Nutrition, Gerber and Nutrition & Santé in 2006. The
divestiture of Medical Nutrition was completed on July 1, 2007.
Group
net sales rise 14% (+11% lc) to USD 19.9 billion
Dynamic
performances from Sandoz and Vaccines and Diagnostics as well as solid
growth in Pharmaceuticals and Consumer Health supported the double-digit
expansion. Higher sales volumes represented seven percentage points of
growth and acquisitions three percentage points, while currency translation
had a positive impact of three points and net price changes added one point.
Pharmaceuticals
net sales advance 12% (+9% lc) to USD 12.0 billion
Ongoing
strong growth in the top-selling brands Diovan (USD 2.4 billion, +19% lc)
and Gleevec/Glivec (USD 1.4 billion, +14% lc) - both No. 1 in their segments
- underpinned the performance. Recently launched brands such as Exforge,
Exjade, Lucentis, Prexige and Tekturna/Rasilez continued growing rapidly.
US net sales rose 5%, as growth in several brands helped offset the impact
of the Zelnorm suspension in March and generic competition for Lotrel starting
in May.
Vaccines
and Diagnostics net sales of USD 482 million
Key
drivers were growth in deliveries of components for use in combination
pediatric vaccines as well as vaccines for tick-borne encephalitis. Diagnostics
products, mainly used for blood testing, delivered further double-digit
growth. The year-ago period included net sales for only two months following
the April 2006 acquisition. Net sales on a comparable basis were up 45%
over the 2006 period recorded by Chiron.
Sandoz
net sales expand 19% (+13% lc) to USD 3.4 billion
Recent
US product launches, in particular for difficult-to-make products, underpinned
the dynamic performance as this region accounted for 28% of total net sales.
Improving positions in markets such as Eastern Europe, Scandinavia, Canada
and Latin America further supported double-digit growth.
Consumer
Health continuing operations net sales up 9% (+6% lc) to USD 2.6 billion
OTC
provided strong growth ahead of the market thanks to strategic brands and
expansion in emerging markets, while Animal Health benefited from further
expansion in key markets.
11/06/07
US court allows Teva to resume US sales of its generic version of Lotrel
Court
denies a request from Novartis to stop ongoing sales of Teva's generic
copy of Lotrel and allows resumption of shipments to customers
Novartis
to continue pursuing its defense of intellectual property rights since
Lotrel has a US patent valid until 2017
Novartis
to launch its own authorized generic version of Lotrel, a high blood pressure
medicine, through its Sandoz generics division
Basel,
June 11, 2007 - Novartis will immediately launch its own generic version
of Lotrel® in the United States through its Sandoz division after a
federal court judge today declined a request from Novartis to stop Teva
Pharmaceuticals from resuming shipments of generic copies of the hypertension
drug.
Novartis
will continue pursuing its defense of intellectual property rights for
Lotrel since its US patent is still valid until 2017. Today's court's
decision allows Teva to resume shipping generic copies of Lotrel. A trial
date has not been set for the ongoing patent infringement lawsuit against
Teva in a New Jersey federal court.
Teva,
which began selling a generic version of Lotrel in the US in May 2007,
risks potentially significant damages if Novartis prevails in patent litigation.
Lotrel,
which is sold only in the US, combines in a single capsule the angiotensin
converting enzyme (ACE) inhibitor benazepril hydrochloride and the calcium
channel blocker (CCB) amlodipine besylate. Both of these active ingredients
no longer have US patent protection.
Financial
update
As
previously announced publicly, Novartis is evaluating the potential impact
of Teva's actions on the full-year 2007 net sales, operating and net income
results. Lotrel had 2006 annual sales of USD 1.35 billion. An update on
the outlook for 2007 will be provided on July 17 when Novartis reports
its 2007 first-half and second-quarter results.
23/04/07
Novartis with dynamic growth in the 2007 first quarter
Strong
2007 first quarter performance as Group net sales advance 18% (+15% in
local currencies) to USD 9.8 billion on excellent performances from all
divisions
Group
continuing operations operating income up 18%, net income up 17%
Four
important new regulatory approvals received in first quarter, significant
progress in achieving multiple new product launches in 2007-2008
Q1
approvals include Tekturna® (hypertension - US), Lucentis® (blindness
- EU), Exforge® (hypertension - EU) and Sebivo® (hepatitis B -
China)
Completion
of strategic positioning on healthcare with pharmaceuticals at the core
Novartis
expects record 2007 operating and net income on a continuing basis and
reaffirms outlook for Group net sales growth of above five percent in local
currencies
Basel,
April 23, 2007- Novartis is off to a strong start in 2007, delivering dynamic
growth in the first quarter as Group net sales rose 18% to USD 9.8 billion
on excellent performances from all divisions and reaffirmed its outlook
for record full-year results.
"I
am pleased with the strong start, enhanced by several new approvals for
innovative medicines that address important unmet medical needs. All divisions,
particularly Pharmaceuticals and Sandoz, delivered excellent performances,"
said Dr. Daniel Vasella, Chairman and CEO of Novartis. "I am confident
of another year of record sales and earnings in 2007."
The
first-quarter performance included four important new regulatory approvals,
including US approval for the hypertension medicine Tekturna® as well
as Lucentis® in Europe for the leading cause of blindness in patients
over age 50, the combination medicine Exforge® for hypertension and
Sebivo® for chronic hepatitis B in China.
Group
operating income advanced 11% to USD 2.5 billion, reflecting the strong
underlying business expansion but growing at a lower rate than net sales
primarily due to a one-time pre-tax divestment gain of USD 129 million
from the sale of the Nutrition & Santé business as part of a
strategy to strategically position Novartis on healthcare.
For
continuing operations during the first quarter, which reflects the divestiture
of Nutrition & Santé as well as Medical Nutrition, Group net
sales were up 19% to USD 9.6 billion and operating income was up 18% to
USD 2.4 billion. The divestiture of the Gerber baby food business, announced
in April, will be reflected in the future as a discontinuing operation.
18/10/05
Novartis
enregistre une croissance soutenue au cours des neuf premiers mois de 2005
et est en bonne voie pour atteindre ses objectifs annuels de chiffre d’affaires
et de bénéfices
20/09/05
Novartis
presents positive Phase III data on key compounds and highlights strong
late-stage development pipeline 
14/07/05
Novartis
enregistre des résultats en forte progression au premier semestre
2005
21/04/05
Novartis
continue de devancer le marché avec un chiffre d'affaires et un
taux de croissance très soutenus au premier trimestre 2005
21/04/05
Novartis
obtient l'autorisation de mise sur le marché en Europe pour Aclasta®
Novartis
affiche des résultats records avec une croissance à deux
chiffres de son chiffre d’affaires net et de son résultat pour 2004 |
